Berlin - Delayed Quote EUR

Enochian BioSciences Inc (2Q5.BE)

Compare
0.8460
-0.0020
(-0.24%)
As of 1:08:05 PM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Expense
24,228.0070
27,388.2960
19,596.8910
22,826.1910
23,401.7870
Operating Income
-24,228.0070
-27,388.2960
-19,596.8910
-22,826.1910
-23,401.7870
Net Non Operating Interest Income Expense
-2,387.3570
-2,434.7710
-706.9640
-250.8030
-366.4290
Other Income Expense
-89,071.8160
-50,827.1050
-19,380.2010
-90,356.3640
-3,080.6670
Pretax Income
-115,687.1800
-80,650.1720
-39,684.0560
-113,433.3580
-26,848.8830
Tax Provision
--
--
--
0.0340
-125.2760
Net Income Common Stockholders
-115,687.1800
-80,650.1720
-39,684.0560
-113,433.3920
-26,723.6070
Diluted NI Available to Com Stockholders
-115,687.1800
-80,650.1720
-39,684.0560
-113,433.3920
-26,723.6070
Basic EPS
-0.98
-0.84
-0.71
-2.16
-0.57
Diluted EPS
-0.98
-0.84
-0.71
-2.16
-0.57
Basic Average Shares
119,269.8950
96,248.0900
56,265.3620
52,528.0240
47,167.2620
Diluted Average Shares
119,269.8950
96,248.0900
56,265.3620
52,528.0240
47,167.2620
Total Operating Income as Reported
-126,093.7360
-81,639.2960
-38,556.8910
-116,079.1910
-23,401.7870
Total Expenses
24,228.0070
27,388.2960
19,596.8910
22,826.1910
23,401.7870
Net Income from Continuing & Discontinued Operation
-115,687.1800
-80,650.1720
-39,684.0560
-113,433.3920
-26,723.6070
Normalized Income
-26,615.3640
-29,823.0670
-20,303.8550
-42,051.8644
-23,657.3143
Interest Income
--
--
--
122.0410
13.1790
Interest Expense
2,505.5800
2,434.7710
706.9640
372.8440
379.6080
Net Interest Income
-2,387.3570
-2,434.7710
-706.9640
-250.8030
-366.4290
EBIT
-113,181.6000
-78,215.4010
-38,977.0920
-113,060.5140
-26,469.2750
EBITDA
-113,054.6160
-78,093.5420
-38,863.5960
-112,936.9240
-26,345.7400
Reconciled Depreciation
126.9840
121.8590
113.4960
123.5900
123.5340
Net Income from Continuing Operation Net Minority Interest
-115,687.1800
-80,650.1720
-39,684.0560
-113,433.3920
-26,723.6070
Total Unusual Items Excluding Goodwill
-89,071.8160
-50,827.1050
-19,380.2010
-90,356.3640
-3,080.6670
Total Unusual Items
-89,071.8160
-50,827.1050
-19,380.2010
-90,356.3640
-3,080.6670
Normalized EBITDA
-23,982.8000
-27,266.4370
-19,483.3950
-22,580.5600
-23,265.0730
Tax Rate for Calcs
--
--
--
0.0002
0.0000
Tax Effect of Unusual Items
--
--
--
-18,974.8364
-14.3743
6/30/2021 - 6/10/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CVAC.VI CureVac N.V.
3.6080
-3.84%
 
BT3.BE Lineage Cell Therapeutics Inc
0.5850
0.00%
 
471A.F aTyr Pharma, Inc.
3.4200
+1.18%
 
1GDA.F Zevra Therapeutics, Inc.
7.40
-3.27%
 
HQ1.MU Oruka Therapeutics Inc. R
11.80
-3.28%
 
ORN.F Oryzon Genomics S.A.
1.4660
+3.97%
 
PH4.F CStone Pharmaceuticals
0.2860
0.00%
 
4FR.BE Faron Pharmaceuticals Oy
2.1900
-0.90%
 
25I.F ImmuPharma plc
0.0605
+168.89%
 
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.4700
-3.09%